AGM Statement

RNS Number : 4068G

Proteome Sciences PLC

29 June 2012

 



Proteome Sciences plc

AGM Statement

29 June 2012 - Our commercial business is developing with great pace.

We delivered strong growth in 2011 and are seeing significant like for like growth in the first half of 2012 and most encouragingly with a much greater contribution expected to come in the second half of the year.

Considerable progress has been made raising our profile through the establishment of a US sales/marketing team and new website in 2011.

The benefits from this will come through from the strong pipeline in products and services.  The number of biomarkers covered by our assays in 2012 will at least double to 100 and these will substantially expand the PS Biomarker Services™ offering and revenues.

The value of IP assets, which includes over 600 patents, is expected to grow sharply as further licenses are concluded and in reagents ThermoScientific is targeting a quantum jump in sales of TMT^® products over the next few years.

The significant revenue growth projected from all three main areas underpins our confidence in Proteome Sciences and our goal of becoming a profitable and self-sustaining business.

Ends

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Chief Executive Officer	Tel: [phone]
Dr. Ian Pike, Chief Operating Officer
James Malthouse, Finance Director
Nominated Adviser
Cenkos
Stephen Keys/Camilla Hume	Tel: [phone]
Public Relations
FTI Consulting	IKON Associates
Ben Atwell / Simon Conway / Mo Noonan	Adrian Shaw
Tel: [phone]	Tel: [phone]

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.

Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag^® (TMT^®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit:  http://www.proteomics.com.

 

END

 

 

AGMFPMITMBJTBPT